Back to search results

Provider Recommendation and HPV Vaccination Study

This study aims to improve vaccination rates for the human papillomavirus (HPV) in children aged 9-12. HPV can cause certain cancers, and many teens are not fully vaccinated. Researchers are comparing two approaches to encourage vaccination: the "Local Tailoring implementation strategy," which involves local teams identifying and addressing barriers, and the "Prescribed Strategy," which uses a standard, evidence-based program. The study is looking at how many children receive their first HPV vaccine dose after one year and again after four years. You may be eligible to participate if you are a parent of a child aged 9-12, or a healthcare provider or administrator in a pediatric clinic at Kaiser Permanente Southern California (KPSC). The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 301,201 participants. It compares two different strategies for improving HPV vaccination rates.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for the proportion of children receiving the first dose of the HPV vaccine at Year 1 and Year 4.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05365048

Provider Recommendation and HPV Vaccination

Recruiting
NAAges 21–70Interventional
Kaiser Permanente
~301,201 participants
Updated 2025-05-20 on ClinicalTrials.gov
What's tested:Local Tailoring implementation strategyPrescribed Strategy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of children 9-12 years old who received the first dose of the HPV vaccine -EMR
Measured over Year 1
+1 more outcome measured

Conditions

Human Papillomavirus

Explore related trials

Human Papillomavirus Infection

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Erin Hahn, PhD · PRINCIPAL_INVESTIGATOR · KPSC Department of Research and Evaluation
  • Chun R Chao, PhD · PRINCIPAL_INVESTIGATOR · KPSC Department of Research and Evaluation

Who to contact

Nancy Takahashi Cannnizzaro, PhD
[email protected]
626-564-7663
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All KPSC pediatric clinics.
All providers (physicians, nurses, and medical assistants) and department administrators from the pediatric department.
Parents of HPV vaccine-eligible children (9-12 years old).

Exclusion

Providers and administrators who do not work for the pediatric department
Parents of children older than 12 years and/or who did not have a clinic visit in the study period.

What this trial measures

  • Proportion of children 9-12 years old who received the first dose of the HPV vaccine -EMRYear 1

    9-12 years old who received the first dose of the HPV vaccine at pre-intervention. Data obtained from electronic medical record (EMR)

  • Proportion of children 9-12 years old who received the first dose of the HPV vaccine - EMRYear 4

    9-12 years old who received the first dose of the HPV vaccine at post-intervention